Cobenfy came to BMS via the pharma giant’s $14 billion acquisition of its developer, Karuna Therapeutics.

Bristol Myers obtained the drug, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics, and is seen as one of the key growth drivers for the drugmaker. Wall Street analysts ...

By the time Cobenfy came to market, he’d been considering last-resort sedatives like benzodiazepines for his 60-something patient, who was by all measures treatment resistant and had been ...

Health Local News Mental Health Hope, caution for WA patients ‘first in line’ for new schizophrenia drug ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...

One of the drugs mentioned in the report is xanomeline/tropsium chloride (Cobenfy; Karuna Therapeutics, acquired by Bristol Myers Squibb), used to treat patients with schizophrenia and psychosis ...

It's a full-circle moment for Cobenfy, which became the first novel type of treatment for the roughly 3 million U.S. adults with schizophrenia in decades after it won approval in September.

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...